New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma
NOD is associated with worse survival outcomes in patients with metastatic and resected PDAC. Reduction of BMI prior to diagnosis of NOD, warrants further investigation to be incorporated into the PDAC screening paradigm.
Authors
- Arun Mavanur (ORCID: https://orcid.org/0000-0003-4755-5938)
- Ana De Jesus‐Acosta (ORCID: https://orcid.org/0000-0002-3225-3024)
- Chirayu Mohindroo (ORCID: https://orcid.org/0000-0002-5825-3356)
- Asha Thomas (ORCID: https://orcid.org/0000-0003-3871-4394)
- Suraj Hande (ORCID: https://orcid.org/0000-0002-3328-7445)
- Florencia McAllister (ORCID: https://orcid.org/0000-0002-9915-0943)
- Paul Stendahl Dy (ORCID: https://orcid.org/0000-0001-6263-1391)
- Christopher R. D’Adamo (ORCID: https://orcid.org/0000-0002-2415-8158)
Institutions
- University of Maryland, Baltimore (US)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- Sinai Hospital (US)
- Johns Hopkins Hospital (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Journal of Gastrointestinal Oncology
- Published
- 2025-02-01
- DOI
- https://doi.org/10.21037/jgo-24-570
- Citations
- 2
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09